Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically-delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease
Published: Dec 10, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics, announced today that it has initiated a Phase 1b clinical trial to evaluate EBI-005, its lead ophthalmic protein product, in patients with dry eye disease. Eleven is rapidly advancing EBI-005, a rationally-designed topical protein that inhibits the IL-1 (Interleukin-1) receptor to treat ocular surface inflammatory disorders. The Phase 1b clinical study, which is expected to complete in the first half of 2013, follows the successful conclusion of the Phase 1a study of EBI-005 in recent weeks.